Back to search results

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

BRAF NP_004324.2:p.V600E · BRAF V600K Mutation Present · Thyroid Gland Anaplastic Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Sasan M. Fazeli, MD) · sfazel@coh.org · 626-218-2332
    Contact: Principal Investigator (Sasan Fazeli, MD)

  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Manisha H. Shah, MD) · manisha.shah@osumc.edu · 614-366-6994
    Contact: Principal Investigator (Manisha H. Shah, MD)

  • Univ of Texas-M.D. Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Naifa Busaudy, MD) · nbusaidy@mdanderson.org · 713-792-2841
Study leads

  • Sasan Fazeli, MD

    Principal Investigator

    City of Hope Medical Center

View source on ClinicalTrials.gov(opens in a new tab)